Image Place holder

Hao Xie, MD, PhD

Specialty: Hematology/Oncology
Program: Gastrointestinal Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Focus: Anal Cancer, Appendiceal (Appendix) Cancer, Cholangiocarcinoma (Bile Duct Cancer), Colon Cancer, Colorectal Cancer , Esophageal Cancer , Gallbladder Cancer , Liver Cancer , Pancreatic Cancer , Rectal Cancer , Small Intestine Cancer , Stomach (Gastric) Cancer

Dr. Hao Xie is as an Assistant Member in the Department of Gastrointestinal Oncology. Dr. Xie’s clinical interests include gastrointestinal cancers and early therapeutics with a focus on the development of clinical trials in colorectal cancer. Dr. Xie is a physician scientist. In addition to his clinical training, he also received a PhD degree in synthetic organic chemistry at Princeton University. His research interests include organic chemistry and chemical biology with a focus on their translation into the discovery of novel drug candidates for advanced colorectal cancer.  

Education & Training

Fellowship:

  • Mayo Clinic - Hematology/Oncology

Residency:

  • Yale University School of Medicine - Internal Medicine

Medical School:

  • Cleveland Clinic Lerner College of Medicine - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Chakrabarti S, Xie H, Urrutia R, Mahipal A. The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review. Cancers (Basel). 2020 Sep.12(10). Pubmedid: 33003583.
  • Yin F, Xie H, Lai J, Chen Y, Dong J, Zhang X, Liu X. Double Negativity for Expression of YAP1 and CDX2 Defines an Aggressive Type of Colitis-associated Cancer. Anticancer Res. 2020 Oct.40(10):5411-5416. Pubmedid: 32988861.
  • Xie H, Mahoney DW, Foote PH, Burger KN, Doering KA, Taylor W, Then SS, Cao X, McGlinch M, Berger CK, Wu TT, Hubbard JM, Allawi HT, Kaiser MW, Lidgard GP, Ahlquist D, Kisiel JB. Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. Clin Cancer Res. 2020 Oct. Pubmedid: 33028593.
  • Xie H, Kaye FJ, Isse K, Sun Y, Ramoth J, French DM, Flotte TJ, Luo Y, Saunders LR, Mansfield AS. Delta-like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. Oncologist. 2020 May. Pubmedid: 32372416. Pmcid: PMC7485334.
  • Xie H, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Gross GG, Loui WS, Hubbard JM, Alberts SR, Grothey A. Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Ther Adv Med Oncol. 2020 Mar.12. Pubmedid: 32201506. Pmcid: PMC7066587.
  • Yin F, Saad M, Xie H, Lin J, Jackson CR, Ren B, Lawson C, Karamchandani DM, Bernabeu BQ, Jiang W, Dhir T, Zheng R, Schultz CW, Zhang D, Thomas CL, Zhang X, Lai J, Schild M, Zhang X, Liu X. Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer. World J Gastrointest Pharmacol Ther. 2020 Jun.11(2):25-39. Pubmedid: 32550043. Pmcid: PMC7288727.
  • Xie H, Liu J, Yin J, Ogden JR, Mahipal A, McWilliams RR, Truty MJ, Bekaii-Saab TS, Petersen GM, Jatoi A, Hubbard JM, Ma WW. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Oncologist. 2020 Jul. Pubmedid: 32663355.
  • Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Couch FJ, Leon Ferre RA, Ruddy KJ. Reply to On the proportion of male breast cancer among all breast cancers. Cancer. 2020 Jan.126(9):2034-2035. Pubmedid: 32012222.
  • Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Couch FJ, Leon-Ferre RA, Ruddy KJ. Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer. 2020 Jan.126(1):26-36. Pubmedid: 31588557.
  • Boland JM, Kroneman TN, Jenkins SM, Terra SBSP, Xie H, Molina J, Mounajjed T, Roden AC. Ki-67 Labeling Index in Pulmonary Carcinoid Tumors: Comparison Between Small Biopsy and Resection Using Tumor Tracing and Hot Spot Methods. Arch Pathol Lab Med. 2020 Jan. Pubmedid: 31944862.
  • Xie H, Liu J, Ogden JR, Yin J, Jatoi A, Hubbard JM, McWilliams RR, Mahipal A, Petersen GM, Bekaii-Saab TS, Ma WW. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Am J Clin Oncol. 2020 Aug.43(8):586-590. Pubmedid: 32349022. Pmcid: PMC7395872.
  • Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, Lutfi F, Siglin J, Hutnick E, Gahres N, Ruehle K, Ahmad H, Shanholtz C, Kocoglu MH, Badros AZ, Yared JA, Hardy NM, Rapoport AP, Dahiya S. Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes. Neurooncol. 2020 Aug. Pubmedid: 32750704.
  • Xie H, Kim RD. The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. Ann Surg Oncol. 2020 Aug. Pubmedid: 32776184.
  • Xie H, Kim RD. ASO Author Reflections: Clinical Utility of Circulating Tumor DNA Analysis in Colorectal Cancer: Current Status. Ann Surg Oncol. 2020 Aug. Pubmedid: 32812106.
  • Xie H, Boland JM, Maleszewski JJ, Aubry MC, Yi ES, Jenkins SM, Koepplin JW, Terra SBSP, Mansfield AS, Roden AC. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors. Lung Cancer. 2019 Sep.135:73-79. Pubmedid: 31447005.
  • Ogden JJ, Xie H, Marks RS, Leventakos K. Two Cases of Krukenberg Tumors from ALK-Rearranged Lung Adenocarcinoma: An Uncommon Site of Metastasis. J Thorac Oncol. 2019 Oct.14(10):e229-e230. Pubmedid: 31558235.
  • Xie H, Liu J, Yadav S, Keutgen X, Hobday T, Strosberg JR, Halfdanarson T. The Role of Perioperative Systemic Therapy in Localized Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology. 2019 May.110(3-4):234-245. Pubmedid: 31121586.
  • Xie H, Adjei AA. Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies. J Thorac Oncol. 2019 Mar.14(3):358-376. Pubmedid: 30599202.
  • Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol. 2019 Feb.42(2):184-189. Pubmedid: 30418178. Pmcid: PMC6345595.
  • Allende DS, Pai RK, Xie H, Liu X. Colorectal Serrated Polyp With Stromal Changes: An Interobserver Agreement Study. Gastroenterology Res. 2019 Dec.12(6):299-304. Pubmedid: 31803309. Pmcid: PMC6879030.
  • Terra SBSP, Xie H, Boland JM, Mansfield AS, Molina JR, Roden AC. Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors. Hum Pathol. 2019 Dec.94:78-85. Pubmedid: 31499081.
  • Riaz IB, Faridi W, Husnain M, Malik SU, Sipra QUAR, Gondal FR, Xie H, Yadav S, Kohli M. Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2019 Aug.94(8):1524-1534. Pubmedid: 31303430.
  • Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, Borah B, Borad MJ, Smoot RL, Roberts LR, Go RS, McWilliams RR, Mahipal A. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. Eur J Surg Oncol. 2019 Aug.45(8):1432-1438. Pubmedid: 30914290.
  • Xie H, Yin J, Shah MH, Menefee ME, Bible KC, Reidy-Lagunes D, Kane MA, Quinn DI, Gandara DR, Erlichman C, Adjei AA. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Invest New Drugs. 2019 Aug.37(4):755-762. Pubmedid: 31172443. Pmcid: PMC7515770.
  • Xie H, Paradise BD, Ma WW, Fernandez-Zapico ME. Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer. Cells. 2019 Apr.8(5). Pubmedid: 31035664. Pmcid: PMC6562674.
  • Jin Z, Zhang D, Zhang Q, Lai J, Akki A, Esnakula A, Kresak J, Gonzalo DH, Draganov PV, Xie H, Liu X. Desmoplasia and Detached Papillae in Early Esophageal Adenocarcinoma: A Histologic Study on Endoscopic Submucosal Dissection Specimens. Gastroenterology Res. 2019 Apr.12(2):72-77. Pubmedid: 31019616. Pmcid: PMC6469900.
  • Ogden JR, Xie H, Ma WW, Hubbard JM. The Management of Older Adults with Pancreatic Adenocarcinoma. Geriatrics (Basel). 2018 Nov.3(4). Pubmedid: 31011120. Pmcid: PMC6371178.
  • Wu XR, Liu HS, Shi XY, Zhou WX, Jiang ZN, Huang Y, Karamchandani DM, Goldblum JR, Xiao SY, Zhu HF, Feely MM, Collinsworth AL, Esnakula A, Xie H, Shen B, Lan P, Liu XL. Interobserver Agreement in the Diagnosis of Inflammatory Bowel Disease-Associated Neoplasia in China in Comparison to Subspecialized American Gastrointestinal Pathologists. Gastroenterol Res Pract. 2018 Apr.2018:8715263. Pubmedid: 29849600. Pmcid: PMC5937390.
  • Horvath B, Allende D, Xie H, Guirguis J, Jeung J, Lapinski J, Patil D, McCullough AJ, Dasarathy S, Liu X. Interobserver Variability in Scoring Liver Biopsies with a Diagnosis of Alcoholic Hepatitis. Alcohol Clin Exp Res. 2017 Sep.41(9):1568-1573. Pubmedid: 28654190. Pmcid: PMC6309429.
  • Roma AA, Park KJ, Xie H, De Vivar AD, Alvarado-Cabrero I, Rutgers JKL, Barbuto D, Silva EG. Role of Lymphovascular Invasion in Pattern C Invasive Endocervical Adenocarcinoma. Am J Surg Pathol. 2017 Sep.41(9):1205-1211. Pubmedid: 28614201.
  • Horvath B, Zhu L, Allende D, Xie H, Guirguis J, Cruise M, Patil DT, O'Shea R, Rivas J, Yordanka R, Lan N, Liu X. Histology and Glutamine Synthetase Immunoreactivity in Liver Biopsies From Patients With Congestive Heart Failure. Gastroenterology Res. 2017 Jun.10(3):182-189. Pubmedid: 28725306. Pmcid: PMC5505284.
  • Roma AA, Liu X, Patil DT, Xie H, Allende D. Proposed Terminology for Anal Squamous Lesions: Its Application and Interobserver Agreement Among Pathologists in Academic and Community Hospitals. Am J Clin Pathol. 2017 Jul.148(1):81-90. Pubmedid: 28605400.
  • Xie H, Adjei AA. Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. Transl Lung Cancer Res. 2017 Dec.6(Suppl 1):S41-S43. Pubmedid: 29299408. Pmcid: PMC5750158.
  • Sun X, Yuan L, Li Y, Shen B, Xie H, Liu X. Association of granulomas in mesenteric lymph nodes in Crohn's disease with younger age and transmural inflammation. J Gastroenterol Hepatol. 2017 Aug.32(8):1463-1468. Pubmedid: 28087973.
  • Horvath B, Singh P, Xie H, Thota PN, Sun X, Liu X. Expression of p53 predicts risk of prevalent and incident advanced neoplasia in patients with Barrett's esophagus and epithelial changes indefinite for dysplasia. Gastroenterol Rep (Oxf). 2016 Nov.4(4):304-309. Pubmedid: 26486567. Pmcid: PMC5193059.
  • Liu G, Lin J, Xie H, Shen B, Stocchi L, Liu X. Histomorphological features and prognosis of colitis-associated colorectal cancer in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2016 May.50(11):1389-1396. Pubmedid: 26061393.
  • Murphy ES, Xie H, Merchant TE, Yu JS, Chao ST, Suh JH. Review of cranial radiotherapy-induced vasculopathy. J Neurooncol. 2015 May.122(3):421-429. Pubmedid: 25670390.
  • Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. J Neurooncol. 2015 Mar.122(1):111-119. Pubmedid: 25534576.
  • Sadraei NH, Dahiya S, Chao ST, Murphy ES, Osei-Boateng K, Xie H, Suh JH, Peereboom DM, Stevens GH, Ahluwalia MS. Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience. Am J Clin Oncol. 2015 Jun.38(3):304-310. Pubmedid: 23799286.
  • Xie H, Tubbs R, Yang B. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. Int J Clin Exp Pathol. 2015 Feb.8(2):1790-1796. Pubmedid: 25973069. Pmcid: PMC4396208.
  • Lai KK, Horvath B, Xie H, Wu X, Lewis BL, Pai RK, Plesec T, Patil DT, Gordon IO, Wang Y, Shen B, Goldblum JR, Liu X. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. Inflamm Bowel Dis. 2015 Feb.21(2):378-384. Pubmedid: 25569733.
  • Li ZG, Zhu H, Shi H, Xie H, Goldblum JR, Thota PN, Liu X. Lymphovascular invasion and nodal metastasis in intramucosal adenocarcinoma of the esophagus and esophagogastric junction. J Dig Dis. 2015 Apr.16(4):197-204. Pubmedid: 25620066.
  • Xie H, Ahluwalia MS, Peereboom DM. The Cleveland Clinic experience with primary central nervous system lymphoma. Am J Clin Oncol. 2015 Apr.38(2):140-146. Pubmedid: 23608829.
  • Dugum M, Askar M, Pai RK, Yerian L, Bennett A, McMahon J, Xie H, Eghtesad B, Hanouneh I, Liu X. Re-examination of sinusoidal deposition of complement 4d in liver allografts: experience from a single institution. Int J Clin Exp Pathol. 2014 Jan.7(2):784-791. Pubmedid: 24551304. Pmcid: PMC3925928.
  • Xie H, Xiao SY, Pai R, Jiang W, Shadrach B, Carver P, Wang Y, Shen B, Zhou W, Liu X. Diagnostic utility of TP53 and cytokeratin 7 immunohistochemistry in idiopathic inflammatory bowel disease-associated neoplasia. Mod Pathol. 2014 Feb.27(2):303-313. Pubmedid: 23887291.
  • Lewis B, Lin J, Wu X, Xie H, Shen B, Lai K, Manilich E, Liu X. Crohn's disease-like reaction predicts favorable prognosis in colitis-associated colorectal cancer. Inflamm Bowel Dis. 2013 Sep.19(10):2190-2198. Pubmedid: 23917251.
  • Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X, Liu X. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 2013 Jan.119(1):173-181. Pubmedid: 22736490.
  • Xie H, Jiang W, Xiao SY, Liu X. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma. J Histochem Cytochem. 2013 Feb.61(2):148-155. Pubmedid: 23124118. Pmcid: PMC3636689.
  • Xie H, Dahiya S, Murphy ES, Chao ST, Suh JH, Stevens GH, Peereboom DM, Ahluwalia MS. Primary central nervous system lymphoma in the elderly: the Cleveland clinic experience. Anticancer Res. 2013 Aug.33(8):3251-3258. Pubmedid: 23898087.
  • Liu X, Melton GB, Xie H, Dietz DW. Extramammary Paget disease in peristomal skin: report of a unique case. J Gastrointest Surg. 2012 Oct.16(10):1967-1971. Pubmedid: 22547349.
  • Xie H, Lin J, Thomas DG, Jiang W, Liu X. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma. Int J Clin Exp Pathol. 2012 Oct.5(4):347-355. Pubmedid: 22670179. Pmcid: PMC3365819.
  • Xie H, Peereboom DM. Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma. J Clin Oncol. 2012 Jul.30(21):e192-e194. Pubmedid: 22711852.
  • Xie H, Sammis GM, Flamme EM, Kraml CM, Sorensen EJ. The catalytic asymmetric Diels-Alder reactions and post-cycloaddition reductive transpositions of 1-hydrazinodienes. Chemistry. 2011 Sep.17(40):11131-11134. Pubmedid: 21898626. Pmcid: PMC3222330.
  • Sammis GM, Flamme EM, Xie H, Ho DM, Sorensen EJ. Design, synthesis, and reactivity of 1-hydrazinodienes for use in organic synthesis. J Am Chem Soc. 2005 Jun.127(24):8612-8613. Pubmedid: 15954764.

Patient Comments
Overall Satisfaction

patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments